Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors is a research paper published in NAR Cancer (2021). On theSindex it has a DataRank of 0. It has been cited 33 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: R01 CA215453-02
America Association of Cancer Research
Grant: 18-40-12-SULE
National Brain Tumor Society
Grant: 2021
NCI NIH HHS
Grant: K08 CA258796
NCI NIH HHS
Grant: R01 CA215453
NCATS NIH HHS
Grant: UL1 TR001863
NCI NIH HHS
Grant: K12 CA215110
NCI NIH HHS
Grant: P30 CA016359
NIAMS NIH HHS
Grant: R01 AR080152
NIGMS NIH HHS
Grant: T32 GM007324
National Institutes of Health
Grant: 2P30CA016359-15
COMPREHENSIVE CANCER CENTER
National Institutes of Health
Grant: 5R01CA215453-03
Exploiting Mutant IDH1/2-induced Homologous Recombination Defects in Cancer
Fields of Study
Keywords
Sustainable Development Goals